Skip to main content

Table 3 Adverse events recorded during treatment

From: Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

Adverse EventsPlacebo N = 21AP N = 23
Serious
Infection
  Herpes simplex virus-1 encephalitis01
  Urinary/pulmonary sepsis, death10
  Pneumonia10
  Influenza10
  Pyelonephritis01
  PML00
Cardiovascular
  Acute coronary syndrome21
  Syncope20
  Pacemaker installation20
Cancer00
Mild – Moderate
Infections
  Upper respiratory tract infection58
  Lower urinary tract infection13
  Gastrointestinal infection22
Other
  Pruriginous rash012
  Dysgeusia03
  Falls24
  Mood/sleep disturbances13
  Gastroesophageal reflux11
  Lumbar pain11
  Joint pain21
  Bursitis01
  Cataract surgery01
  Gastric ulcer10
  Vertigo10
  Constipation10
  1. Comorbidities were balanced between groups (data not shown)